Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 5/2014

01.10.2014 | Clinical Review

Clinical features and management of type I gastric carcinoids

verfasst von: Yuichi Sato

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Type I gastric carcinoids (TIGCs) are related to chronic atrophic gastritis and are characterized by hypergastrinemia and hyperplasia of enterochromaffin-like cells. TIGCs are the most frequently diagnosed of all gastric carcinoids, accounting for about 70–80 %. Endoscopically, TIGCs are present as small (<10 mm), polypoid lesions or, more frequently, as smooth, rounded submucosal lesions. Histologically, TIGCs arise in the deep mucosa, with some invading the submucosa. Most TIGCs are well-differentiated tumors, with metastasis being rare. Therefore, patients with TIGCs generally have an excellent prognosis. Among the currently available treatment options are total gastrectomy, partial resection, antrectomy, endoscopic resection, and endoscopic surveillance, although no consensus has been reached on their optimal management. Further studies are needed to develop better management options for patients with TIGC.
Literatur
1.
Zurück zum Zitat Solcia E, Arnold R, Capella C, et al. Neuroendocrine neoplasms of the stomach. In: Bosman FT, Carneiro F, Hruban RH, Theise ND editors WHO classification of tumours of the digestive system. Lyon: IARC, 2010. p. 64–68. Solcia E, Arnold R, Capella C, et al. Neuroendocrine neoplasms of the stomach. In: Bosman FT, Carneiro F, Hruban RH, Theise ND editors WHO classification of tumours of the digestive system. Lyon: IARC, 2010. p. 64–68.
2.
Zurück zum Zitat Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.PubMedCrossRef Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.PubMedCrossRef
3.
Zurück zum Zitat Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105:2563–9.PubMedCrossRef Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105:2563–9.PubMedCrossRef
4.
Zurück zum Zitat Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99:23–32.PubMedCrossRef Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99:23–32.PubMedCrossRef
5.
Zurück zum Zitat Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathological study. Gastroenterology. 1993;104:994–1006.PubMed Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathological study. Gastroenterology. 1993;104:994–1006.PubMed
6.
Zurück zum Zitat Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract. 2012; Article ID 287825. Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract. 2012; Article ID 287825.
7.
Zurück zum Zitat Basuroy R, Srirajaskanthan R, Prachalias A, et al. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 2014;39:1071–84.PubMedCrossRef Basuroy R, Srirajaskanthan R, Prachalias A, et al. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 2014;39:1071–84.PubMedCrossRef
8.
Zurück zum Zitat Li TT, Qiu F, Qian ZR, et al. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol. 2014;20:118–25.PubMedCrossRefPubMedCentral Li TT, Qiu F, Qian ZR, et al. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol. 2014;20:118–25.PubMedCrossRefPubMedCentral
9.
Zurück zum Zitat Massironi S, Sciola V, Spampatti MP, et al. Gastric carcinoids: between underestimation and overtreatment. World J Gastroenterol. 2009;15:2177–83.PubMedCrossRefPubMedCentral Massironi S, Sciola V, Spampatti MP, et al. Gastric carcinoids: between underestimation and overtreatment. World J Gastroenterol. 2009;15:2177–83.PubMedCrossRefPubMedCentral
10.
Zurück zum Zitat Zhang L, Ozao J, Warner R, Divino C. Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor. World J Surg. 2011;35:1879–86.PubMedCrossRef Zhang L, Ozao J, Warner R, Divino C. Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor. World J Surg. 2011;35:1879–86.PubMedCrossRef
11.
Zurück zum Zitat Kaltsas G, Grozinsky-Glasberg S, Alexandraki KI, et al. Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf). 2014;81:157–68.CrossRef Kaltsas G, Grozinsky-Glasberg S, Alexandraki KI, et al. Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf). 2014;81:157–68.CrossRef
12.
Zurück zum Zitat Scherübl H, Cadiot G, Jensen RT, et al. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy. 2010;42:664–71.PubMedCrossRef Scherübl H, Cadiot G, Jensen RT, et al. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy. 2010;42:664–71.PubMedCrossRef
13.
Zurück zum Zitat Sato Y, Iwafuchi M, Ueki J, et al. Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection. Dig Dis Sci. 2002;47:579–85.PubMedCrossRef Sato Y, Iwafuchi M, Ueki J, et al. Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection. Dig Dis Sci. 2002;47:579–85.PubMedCrossRef
14.
Zurück zum Zitat Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234–43.PubMedCrossRef Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234–43.PubMedCrossRef
15.
Zurück zum Zitat Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17:909–18.PubMedCrossRef Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17:909–18.PubMedCrossRef
16.
Zurück zum Zitat Cho MY, Kim JM, Sohn JH, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (gep-nets) in korea 2000–2009: multicenter study. Cancer Res Treat. 2012;44:157–65.PubMedCrossRefPubMedCentral Cho MY, Kim JM, Sohn JH, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (gep-nets) in korea 2000–2009: multicenter study. Cancer Res Treat. 2012;44:157–65.PubMedCrossRefPubMedCentral
17.
Zurück zum Zitat Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:1–18.PubMedCrossRef Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:1–18.PubMedCrossRef
18.
Zurück zum Zitat Soykan I, Yakut M, Keskin O, et al. Clinical profiles, endoscopic and laboratory features and associated factors in patients with autoimmune gastritis. Digestion. 2012;86:20–6.PubMedCrossRef Soykan I, Yakut M, Keskin O, et al. Clinical profiles, endoscopic and laboratory features and associated factors in patients with autoimmune gastritis. Digestion. 2012;86:20–6.PubMedCrossRef
19.
Zurück zum Zitat Sato Y, Imamura H, Kaizaki Y, et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc. 2014;26:377–84.PubMedCrossRef Sato Y, Imamura H, Kaizaki Y, et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc. 2014;26:377–84.PubMedCrossRef
20.
Zurück zum Zitat Higham AD, Bishop LA, Dimaline R, et al. Mutations of RegI alpha are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. Gastroenterology. 1999;116:1310–8.PubMedCrossRef Higham AD, Bishop LA, Dimaline R, et al. Mutations of RegI alpha are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. Gastroenterology. 1999;116:1310–8.PubMedCrossRef
21.
Zurück zum Zitat Pritchard DM, Berry D, Przemeck SM, et al. Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. Am J Physiol Gastrointest Liver Physiol. 2008;295:G798–805.PubMedCrossRefPubMedCentral Pritchard DM, Berry D, Przemeck SM, et al. Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. Am J Physiol Gastrointest Liver Physiol. 2008;295:G798–805.PubMedCrossRefPubMedCentral
22.
Zurück zum Zitat D’Adda T, Keller G, Bordi C, Höfler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest. 1999;79:671–7.PubMed D’Adda T, Keller G, Bordi C, Höfler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest. 1999;79:671–7.PubMed
23.
Zurück zum Zitat Chittajulla RS, Ardill JES, McColl KEL. The degree of hypergastrinemia induced by Helicobacter pylori is the same in duodenal ulcer patients and asymptomatic volunteers. Eur J Gastroenterol. 1992;4:49–53. Chittajulla RS, Ardill JES, McColl KEL. The degree of hypergastrinemia induced by Helicobacter pylori is the same in duodenal ulcer patients and asymptomatic volunteers. Eur J Gastroenterol. 1992;4:49–53.
24.
Zurück zum Zitat Smith JTL, Pounder RE, Nwokolo CU. Inappropriate hypergastrinemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut. 1990;31:522.PubMedCrossRefPubMedCentral Smith JTL, Pounder RE, Nwokolo CU. Inappropriate hypergastrinemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut. 1990;31:522.PubMedCrossRefPubMedCentral
25.
Zurück zum Zitat El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 1997;113:15–24.PubMedCrossRef El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 1997;113:15–24.PubMedCrossRef
26.
Zurück zum Zitat Faller G, Steininger H, Kra¨nzlein J, et al. Antigastric autoantibodies in Helicobacter pylori infection: implications of histological and clinical parameters of gastritis. Gut. 1997;41:619–23.PubMedCrossRefPubMedCentral Faller G, Steininger H, Kra¨nzlein J, et al. Antigastric autoantibodies in Helicobacter pylori infection: implications of histological and clinical parameters of gastritis. Gut. 1997;41:619–23.PubMedCrossRefPubMedCentral
27.
Zurück zum Zitat Claeys D, Faller G, Appelmelk BJ, et al. The gastric H, K+–ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology. 1998;115:340–7.PubMedCrossRef Claeys D, Faller G, Appelmelk BJ, et al. The gastric H, K+–ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology. 1998;115:340–7.PubMedCrossRef
28.
Zurück zum Zitat Negrini R, Savio A, Poiesi C, et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology. 1996;111:655–65.PubMedCrossRef Negrini R, Savio A, Poiesi C, et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology. 1996;111:655–65.PubMedCrossRef
29.
Zurück zum Zitat Calam J, Gibbons A, Healey ZV, et al. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology. 1997;113:S43–9.PubMedCrossRef Calam J, Gibbons A, Healey ZV, et al. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology. 1997;113:S43–9.PubMedCrossRef
30.
Zurück zum Zitat Kidd M, Miu K, Tang LH, et al. Helicobacter pylori lipopolysaccharide stimulates histamine release and DNA synthesis in rat enterochromaffin- like cells. Gastroenterology. 1997;113:1110–7.PubMedCrossRef Kidd M, Miu K, Tang LH, et al. Helicobacter pylori lipopolysaccharide stimulates histamine release and DNA synthesis in rat enterochromaffin- like cells. Gastroenterology. 1997;113:1110–7.PubMedCrossRef
31.
Zurück zum Zitat Solcia E, Rindi G, Fiocca R, et al. Distinct patterns of chronic gastritis associated with carcinoid and cancer and their role in tumorigenesis. Yale J Biol Med. 1992;65:793–804.PubMedPubMedCentral Solcia E, Rindi G, Fiocca R, et al. Distinct patterns of chronic gastritis associated with carcinoid and cancer and their role in tumorigenesis. Yale J Biol Med. 1992;65:793–804.PubMedPubMedCentral
32.
Zurück zum Zitat Ravizza D, Fiori G, Trovato C, et al. Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Dig Liver Dis. 2007;39:537–43.PubMedCrossRef Ravizza D, Fiori G, Trovato C, et al. Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Dig Liver Dis. 2007;39:537–43.PubMedCrossRef
33.
Zurück zum Zitat Borch K, Ahrén B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242:64–73.PubMedCrossRefPubMedCentral Borch K, Ahrén B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242:64–73.PubMedCrossRefPubMedCentral
34.
Zurück zum Zitat Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut. 1998;43:223–8.PubMedCrossRefPubMedCentral Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut. 1998;43:223–8.PubMedCrossRefPubMedCentral
35.
Zurück zum Zitat Ichikawa J, Tanabe S, Koizumi W, et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy. 2003;35:203–6.PubMedCrossRef Ichikawa J, Tanabe S, Koizumi W, et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy. 2003;35:203–6.PubMedCrossRef
36.
Zurück zum Zitat Singh R, Yao K, Anagnostopoulos G, et al. Microcarcinoid tumor diagnosed with high-resolution magnification endoscopy and narrow band imaging. Endoscopy. 2008;40(Suppl 2):E12.PubMedCrossRef Singh R, Yao K, Anagnostopoulos G, et al. Microcarcinoid tumor diagnosed with high-resolution magnification endoscopy and narrow band imaging. Endoscopy. 2008;40(Suppl 2):E12.PubMedCrossRef
37.
Zurück zum Zitat Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95:74–87.PubMedCrossRef Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95:74–87.PubMedCrossRef
39.
Zurück zum Zitat Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion. 1988;41:185–200.PubMedCrossRef Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion. 1988;41:185–200.PubMedCrossRef
40.
Zurück zum Zitat Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban R, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on cancer (IARC); 2010. p. 13–14. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban R, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on cancer (IARC); 2010. p. 13–14.
41.
Zurück zum Zitat Karaca C, Turner BG, Cizginer S, Forcione D, Brugge W. Accuracy of EUS in the evaluation of small gastric subepithelial lesions. Gastrointest Endosc. 2010;71:722–7.PubMedCrossRef Karaca C, Turner BG, Cizginer S, Forcione D, Brugge W. Accuracy of EUS in the evaluation of small gastric subepithelial lesions. Gastrointest Endosc. 2010;71:722–7.PubMedCrossRef
42.
Zurück zum Zitat Bushnell DL, Baum RP. Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:153–62.PubMedCrossRef Bushnell DL, Baum RP. Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:153–62.PubMedCrossRef
43.
Zurück zum Zitat Gibril F, Reynolds JC, Lubensky IA, et al. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med. 2000;41:1646–56.PubMed Gibril F, Reynolds JC, Lubensky IA, et al. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med. 2000;41:1646–56.PubMed
44.
Zurück zum Zitat O’Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:719–35.PubMedCrossRef O’Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:719–35.PubMedCrossRef
45.
Zurück zum Zitat La Rosa S, Inzani F, Vanoli A, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42:1373–84.PubMedCrossRef La Rosa S, Inzani F, Vanoli A, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42:1373–84.PubMedCrossRef
46.
Zurück zum Zitat Saund MS, Al Natour RH, Sharma AM, et al. Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. Ann Surg Oncol. 2011;18:2826–32.PubMedCrossRef Saund MS, Al Natour RH, Sharma AM, et al. Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. Ann Surg Oncol. 2011;18:2826–32.PubMedCrossRef
47.
Zurück zum Zitat Grozinsky-Glasberg S, Thomas D, Strosberg JR, et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol. 2013;19:8687–95.PubMedCrossRefPubMedCentral Grozinsky-Glasberg S, Thomas D, Strosberg JR, et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol. 2013;19:8687–95.PubMedCrossRefPubMedCentral
48.
Zurück zum Zitat Gilligan CJ, Lawton GP, Tang LH, et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol. 1995;90:338–52.PubMed Gilligan CJ, Lawton GP, Tang LH, et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol. 1995;90:338–52.PubMed
49.
Zurück zum Zitat Hosokawa O, Kaizaki Y, Hattori M, et al. Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer. 2005;8:42–6.PubMedCrossRef Hosokawa O, Kaizaki Y, Hattori M, et al. Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer. 2005;8:42–6.PubMedCrossRef
50.
Zurück zum Zitat Kulke MH, Benson AB 3rd, Bergsland E, et al. National comprehensive cancer networks. neuroendocrine tumors. J Natl Compr Canc Netw. 2012;10:724–64.PubMed Kulke MH, Benson AB 3rd, Bergsland E, et al. National comprehensive cancer networks. neuroendocrine tumors. J Natl Compr Canc Netw. 2012;10:724–64.PubMed
51.
Zurück zum Zitat Sato Y, Takeuchi M, Hashimoto S, et al. Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection. Hepatogastroenterology. 2013;60:1524–7.PubMed Sato Y, Takeuchi M, Hashimoto S, et al. Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection. Hepatogastroenterology. 2013;60:1524–7.PubMed
52.
Zurück zum Zitat Kim HH, Kim GH, Kim JH, Choi MG, Song GA, Kim SE. The efficacy of endoscopic submucosal dissection of type I gastric carcinoid tumors compared with conventional endoscopic mucosal resection. Gastroenterol Res Pract. 2014; 253860. doi:10.1155/2014/253860. Epub 17 Feb 2014. Kim HH, Kim GH, Kim JH, Choi MG, Song GA, Kim SE. The efficacy of endoscopic submucosal dissection of type I gastric carcinoid tumors compared with conventional endoscopic mucosal resection. Gastroenterol Res Pract. 2014; 253860. doi:10.​1155/​2014/​253860. Epub 17 Feb 2014.
53.
Zurück zum Zitat Gladdy RA, Strong VE, Coit D, Allen PJ, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16:3154–60.PubMedCrossRef Gladdy RA, Strong VE, Coit D, Allen PJ, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16:3154–60.PubMedCrossRef
54.
Zurück zum Zitat Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol. 2013;168:185–93.PubMedCrossRef Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol. 2013;168:185–93.PubMedCrossRef
55.
Zurück zum Zitat Grozinsky-Glasberg S, Kaltsas G, Gur C, et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol. 2008;159:475–82.PubMedCrossRef Grozinsky-Glasberg S, Kaltsas G, Gur C, et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol. 2008;159:475–82.PubMedCrossRef
56.
Zurück zum Zitat Campana D, Nori F, Pezzilli R, et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer. 2008;15:337–42.PubMedCrossRef Campana D, Nori F, Pezzilli R, et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer. 2008;15:337–42.PubMedCrossRef
57.
Zurück zum Zitat Jianu CS, Fossmark R, Syversen U, et al. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol. 2011;46:456–63.PubMedCrossRef Jianu CS, Fossmark R, Syversen U, et al. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol. 2011;46:456–63.PubMedCrossRef
58.
Zurück zum Zitat Fossmark R, Sørdal Ø, Jianu CS, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012;36:1067–75.PubMedCrossRef Fossmark R, Sørdal Ø, Jianu CS, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012;36:1067–75.PubMedCrossRef
Metadaten
Titel
Clinical features and management of type I gastric carcinoids
verfasst von
Yuichi Sato
Publikationsdatum
01.10.2014
Verlag
Springer Japan
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 5/2014
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-014-0528-9

Weitere Artikel der Ausgabe 5/2014

Clinical Journal of Gastroenterology 5/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.